氯沙坦
CYP2C9
医学
高尿酸血症
内科学
血压
尿酸
内分泌学
尿
药理学
血管紧张素II
胃肠病学
新陈代谢
细胞色素P450
作者
Ирина Синицина,Alexey V Boyarko,И. И. Темирбулатов,D. А. Sychev,Kristina Ryzhikova,Ж. А. Созаева,Elena A. Grishina,К. Б. Мирзаев,Anastasiia V. Asoskova,Владимир Петрович Фисенко
出处
期刊:Drug metabolism and personalized therapy
[De Gruyter]
日期:2022-12-29
卷期号:38 (2): 163-168
被引量:3
标识
DOI:10.1515/dmpt-2022-0115
摘要
CYP2C9 gene polymorphic variants can decrease the effects of losartan, reducing active metabolite (E-3174) formation. Study aims to determine the influence of *2 (+430C>T; rs799853) and *3 (+1075A>C; rs1057910) CYP2C9 gene polymorphic variants on the hypotensive and uricosuric effect of losartan on patients with arterial hypertension.Eighty one patients with stage 1-2 arterial hypertension newly diagnosed with ABMP were enrolled in the study. Physicians started losartan treatment and then we measured urine concentration of E-3174/losartan to estimate CYP2C9 activity. After 3-month losartan treatment we compared effectiveness of the therapy with ABPM and plasma uric acid level between carriers of CYP2C9 *1/*1 and CYP2C9 gene polymorphic variants (*2 and *3).Carriage of CYP2C9*2 and CYP2C9*3 alleles reduced the hypotensive effect of losartan (p<0.001, OR=8.13 (95% CI, 2.75-23.97)). Analysis of the ABPM data revealed that blood pressure was significantly higher in patients with polymorphic genotypes. There was no significant difference in uric acid level in plasma and losartan and its metabolite concentration in urine between genotypes.Carriage of low function polymorphic variants of the CYP2C9 gene (*2 and *3) reduced the hypotensive effect of losartan according to ABPM and don't affect uric acid level in plasma and E-3174/losartan in urine.
科研通智能强力驱动
Strongly Powered by AbleSci AI